Due to its specific overexpression and role in mediating MM progression and survival, IRF4 is actively being pursued as a therapeutic target, with novel direct small molecule inhibitors that bind its DNA-binding domain being designed and synthesized 54 and antisense oligonucleotide-based approaches being explored to silence its expression 55. This evidence concerns the gene IRF4 and Miyoshi myopathy.